文献速递生殖医学

短期二甲双胍不能降低接受体外受精的多囊卵巢综合征女性在促性腺激素释放激素拮抗剂周期中的卵巢过度刺激综合征发生率:一项随机安慰剂对照试验

A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial.
PubMed 文献 · Hum Reprod · 2016-11-05

本研究为随机安慰剂对照试验,纳入153例符合鹿特丹标准的多囊卵巢综合征(PCOS)患者,在接受促性腺激素释放激素(GnRH)拮抗剂体外受精/卵胞浆内单精子注射(IVF/ICSI)周期中,从刺激前至取卵日使用二甲双胍或安慰剂。结果显示,二甲双胍组中重度卵巢过度刺激综合征(OHSS)发生率为16%,安慰剂组为12.2%,差异无统计学意义(95%CI -0.08-0.16,P=0.66);但二甲双胍组临床妊娠率(28.6% vs 48.7%,P=0.02)和活产率(27.6% vs 51.6%,P=0.02)均显著低于安慰剂组。

要点

  • 短期二甲双胍未降低PCOS患者GnRH拮抗剂周期中重度OHSS发生率(16% vs 12.2%,P=0.66)。
  • 二甲双胍组临床妊娠率(28.6% vs 48.7%)和活产率(27.6% vs 51.6%)均显著低于安慰剂组。
  • 南亚裔人群妊娠结局显著低于白种人(临床妊娠率19.4% vs 44.4%,P=0.01),与用药无关。

核心结论

  • 短期二甲双胍不降低PCOS患者GnRH拮抗剂周期中OHSS发生率。
  • 该研究不支持将二甲双胍作为GnRH拮抗剂周期的经验性辅助用药。

研究设计与样本

  • 随机安慰剂对照试验,采用随机排列区组法,50:50分配比例,患者与研究者双盲。
  • 研究历时5年(2009-2014年),共随机153例,二甲双胍组77例,安慰剂组76例。
  • 样本量计算基于OHSS发生率,前瞻性完成,把握度80%、Ⅰ型错误0.05时需至少146例。
  • 所有患者符合PCOS鹿特丹标准,在一家三级不孕症门诊接受标准GnRH拮抗剂IVF/ICSI周期治疗。
  • 研究药物从刺激前开始使用,持续至取卵日。

主要发现

  • 中重度OHSS发生率:安慰剂组12.2% vs 二甲双胍组16%(95%CI -0.08-0.16,P=0.66),无显著差异。
  • 促性腺激素总剂量:安慰剂组1200 vs 二甲双胍组1200(95%CI -118.67-118.67,P=0.75),无显著差异。
  • 获卵数:安慰剂组15 vs 二甲双胍组14(95%CI -2.37-4.37,P=0.66),无显著差异。
  • 受精率:安慰剂组60.7% vs 二甲双胍组53.3%(95%CI -0.96-14.94,P=0.07),无显著差异。
  • 每启动周期临床妊娠率:安慰剂组48.7% vs 二甲双胍组28.6%(95%CI 0.04-0.35,P=0.02),二甲双胍组降低。

临床怎么用

  • 作者认为,该研究不支持将二甲双胍作为GnRH拮抗剂治疗周期的经验性辅助用药。

局限性

  • 本研究仅在不孕症PCOS人群中进行,且研究药物使用时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does 'metformin' reduce the incidence of ovarian hyperstimulation syndrome (OHSS) for women with polycystic ovary syndrome (PCOS) undergoing a GnRH antagonist assisted conception treatment cycle? SUMMARY ANSWER: A short course of metformin does not reduce the incidence of OHSS for women with PCOS undergoing a GnRH antagonist treatment cycle. WHAT IS KNOWN ALREADY: Metformin does reduce the incidence of OHSS in a GnRH-agonist treatment cycle. STUDY DESIGN, SIZE, DURATION: A randomised placebo-controlled trial (RCT) using metformin or placebo. Randomisation was blinded to both patient and investigator, using a random permuted blocks method with a 50:50 allocation ratio. The study was completed over 5 years (2009-2014) with 153 randomised patients. A sample size calculation based on the incidence of OHSS was completed prospectively suggesting a minimum of 146 recruits was required for the trial with a power of 80% and a type 1 error of 0.05. PARTICIPANTS/MATERIALS, SETTING, METHODS: All patients met the Rotterdam criteria for PCOS and were treated with a standard GnRH antagonist IVF/ICSI treatment cycle in a tertiary infertility clinic. The study medication was started prior to stimulation and continued to oocyte retrieval. Of the 153 patients, 77 received metformin and 76 placebo. MAIN RESULTS AND THE ROLE OF CHANCE: There was no reduction in the incidence of moderate-severe OHSS (Placebo (PLA) 12.2%, metformin (MET) = 16%, 95% CI -0.08-0.16, P = 0.66). There was no difference in total gonadotrophin dose (PLA = 1200, MET = 1200, 95% CI -118.67-118.67, P = 0.75), oocytes retrieved (PLA = 15, MET = 14, 95% CI -2.37-4.37, P = 0.66) or fertilisation rate (PLA = 60.7%, MET = 53.3%, 95% CI -0.96-14.94, P = 0.07). However, using metformin resulted in a reduced clinical pregnancy rate (CPR) per cycle started (PLA = 48.7%, MET = 28.6%, 95% CI 0.04-0.35, P = 0.02) and live birth rate (PLA = 51.6%, MET = 27.6%, 95% CI 0.05-0.40, P = 0.02). Furthermore, when ethnicity was taken into account there was a significant reduction in pregnancy outcome for the South Asian population irrespective of metformin or placebo use (CPR per cycle started, White Caucasian = 44.4%, South Asian = 19.4%; 95% CI 0.06-0.39, P = 0.01). LIMITATIONS, REASONS FOR CAUTION: This study was only undertaken on an infertility population with PCOS with a limited duration of study medication use. WIDER IMPLICATIONS OF THE FINDINGS: This is the first adequately powered RCT to assess the impact of metformin on OHSS in a high-risk group (women with PCOS) undergoing a GnRH antagonist cycle. It does not support the empirical prescribing of metformin as an adjunct to a GnRH antagonist treatment cycle. STUDY FUNDING/COMPETING INTERESTS: None. TRIAL REGISTRATION NUMBER: EudraCT number 2009-010952-81. TRIAL REGISTRATION DATE: 21 September 2009. DATE OF FIRST PATIENT'S ENROLMENT: 30 October 2009.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Jacob SL, Brewer C, Tang T, et al. A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Hum Reprod. 2016. PMID: 27816925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。